Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief
March 16, 2017
- Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Takeda Revving Up Partnership Initiatives
March 15, 2017
- Maruho Gets Global Rights to Toray’s RORγt Inhibitor
March 15, 2017
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Daiichi Sankyo Taps Heptares for Pain Med Discovery Research
March 14, 2017
- Daiichi Sankyo Launches Large-Scale Observational Study for Cancer VTE
March 14, 2017
- Toyama Chemical, Towa Settle Patent Suit over Ozex Pediatric Drug
March 14, 2017
- Canada’s Duchesnay Gets Rights to Shionogi’s Osphena in North America
March 14, 2017
- Debiopharm Brings Towa before Supreme Court over Elplat
March 14, 2017
- 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
- Yoshiki Ito Named as New Alexion Japan President
March 14, 2017
- Pfizer Initiates Voluntary Recall of EpiPen 0.3 mg in Japan
March 14, 2017
- UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs
March 13, 2017
- Eisai CEO Has High Hopes on Combinations of Alzheimer’s Pipelines
March 10, 2017
- Takecab Most Heavily Pitched Drug in HP Market in January: Anterio
March 9, 2017
- Yutaka Shibata to Helm Asahi Kasei Pharma
March 9, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…